Table 5.
Univariate analysis of PFS and OS in our study population (N = 38).
| PFS | OS | |
|---|---|---|
| p-value | p-value | |
| GENDER | 0.3 | 0.2 |
| Male/Female | ||
| N° OF COMORBIDITIES | 0.8 | 0.8 |
| < 3/≥3 | ||
| HYSTOLOGY | 0.3 | 0.8 |
| Clear Cells/Other | ||
| AGE | 0.4 | 0.003 |
| < 70 years/≥70 years | ||
| KARNOFSKY PS | 0.2 | 0.02 |
| < 80%/≥80% | ||
| PRIOR NEPHRECTOMY | 0.6 | 0.03 |
| Yes/No | ||
| METASTATIC OF SITES | 0.08 | 0.4 |
| ≤ 5/≥6 | ||
| DYSTHYROIDISM | 0.04 | 0.8 |
| No/Yes | ||
| HYPERTENSION | 0.6 | 0.02 |
| No/G1-2/G≥3 | ||
| HEPATOTOXICITY | 0.6 | 0.8 |
| G1-2/G≥3/No Toxicity | ||
| TUMOR RESPONSE RATE | 0.002 | 0.2 |
| DCR | 0.0001 | DCR |
| DCR (CR + PR + SD)/PD | ||
PFS, progression-free survival; OS, overall survival; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; DCR, disease control rate; PS, performance status.